Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value

Core Viewpoint - Keros Therapeutics, Inc. is urging stockholders to vote in favor of its three director nominees during the upcoming Annual Meeting, emphasizing the importance of protecting stockholder value amid a strategic review process aimed at maximizing investment returns [2][3][5]. Company Overview - Keros is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß protein family [21]. - The company has a differentiated clinical pipeline, including three key product candidates: KER-065 for neuromuscular diseases, elritercept (KER-050) for cytopenias, and cibotercept (KER-012) for pulmonary arterial hypertension [6][21]. Strategic Review Process - The Board of Directors is conducting a comprehensive strategic review to evaluate options for maximizing stockholder value, including potential sales, continued investment in the pipeline, or returning excess capital [4][10]. - An interim update on the strategic review process is expected by June 9, 2025 [11]. Director Nominees - Keros recommends stockholders vote "FOR" its three director nominees: Mary Ann Gray, Ph.D., Ran Nussbaum, and Alpna Seth, Ph.D., highlighting their qualifications and experience in the biopharmaceutical industry [3][5][16]. Financial Partnerships - Keros has established a partnership with Takeda Pharmaceuticals, which includes a $200 million upfront payment and potential milestones of up to $1.1 billion, enhancing its financial position and supporting its development goals [11][12]. Clinical Development Updates - KER-065 is advancing to a Phase 2 clinical trial for Duchenne muscular dystrophy (DMD) in early 2026, pending regulatory interactions [6][11]. - Elritercept is being developed for low blood cell counts in patients with myelodysplastic syndromes and myelofibrosis, with significant potential benefits for patients with limited treatment options [12][21]. - Cibotercept's Phase 2 trial (TROPOS) was terminated early due to safety concerns, and the company plans to evaluate its development strategy post-trial [12][21]. Board Composition - The Keros Board consists of nine independent directors, with a significant portion representing stockholder interests, which is higher than the median of its performance peer group [14][15].